{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:05:43Z","timestamp":1789477543489,"version":"build-2803163510"},"reference-count":108,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NEXUS PEOPLE, S.L."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Comparative effects of oral second-generation H1-antihistamines vary by rhinitis category, outcome, and treatment period. We assessed evidence structure, estimability, and differentiation among regimens. Methods: PubMed, Embase, Web of Science Core Collection, CENTRAL, WHO ICTRP, ClinicalTrials.gov, and the EU Clinical Trials Register were searched on 1\u20133 July 2026 for records through 30 June 2026. Eligible studies were natural-exposure randomized trials. Continuous outcomes were analyzed using covariance-aware generalized least squares, and binary harms were analyzed using Bayesian arm-level models. RoB 2, CINeMA, and ROB-MEN were applied in duplicate. Registration was retrospective. Results: Sixty-one reports generated 66 report\u2013randomization entries from 64 cohorts (34,831 participants); 35 model-ready randomizations informed nine structures. In seasonal allergic rhinitis, six of seven TNSS estimates, two of three ocular estimates, and four RQLQ estimates favored active treatment. Any-adverse-event estimates were imprecise. Under the primary prior, cetirizine yielded a WDAE OR of 0.25 (95% CrI 0.08\u20130.66), but predictive classification was prior-sensitive. Of 34 continuous active\u2013active comparisons, seven were directly informed and 27 indirect-only. All 147 estimable binary active\u2013active contrasts were reported as secondary derivations: 141 CrIs included one and six excluded one, all indirect-only and not formally appraised with CINeMA. Six of 14 regimen-level nodes contributed only to tolerability structures, precluding balanced regimen-specific benefit\u2013harm assessment. All 89 estimable comparisons within the defined CINeMA appraisal scope were rated very low; two non-estimable effects were not evaluable. Conclusions: Predominantly placebo-anchored and sparse evidence established neither a reliable regimen hierarchy nor therapeutic equivalence. Findings were hypothesis-generating, and somnolence remained an evidence gap. No external funding supported conduct; NEXUS PEOPLE, S.L. funded the APC. OSF registration was retrospective: doi:10.17605\/OSF.IO\/DPT5N.<\/jats:p>","DOI":"10.3390\/jcm15187169","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:57:34Z","timestamp":1789473454000},"page":"7169","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral Second-Generation H1-Antihistamine Regimens for Allergic Rhinitis: Systematic Review and Network Meta-Analysis of Effects and Estimability"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4782-7942","authenticated-orcid":false,"given":"Jos\u00e9 David","family":"Maya Viejo","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Camas, 41900 Camas, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2401-2319","authenticated-orcid":false,"given":"Fernando Mar\u00eda","family":"Navarro i Ros","sequence":"additional","affiliation":[{"name":"Centro de Salud Plaza Segovia, 46017 Val\u00e8ncia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Trillo-Calvo","sequence":"additional","affiliation":[{"name":"Centro de Salud Campo de Belchite, 50130 Belchite, Zaragoza, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n (IIS Arag\u00f3n), Avenida San Juan Bosco 13, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Richard","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Centro de Salud Puerto de Santa Mar\u00eda Sur, 11500 Puerto de Santa Mar\u00eda, C\u00e1diz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2024.0530","article-title":"Allergic rhinitis: A review","volume":"331","author":"Bernstein","year":"2024","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1398-9995.2007.01620.x","article-title":"Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update","volume":"63","author":"Bousquet","year":"2008","journal-title":"Allergy"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jaci.2017.03.050","article-title":"Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision","volume":"140","author":"Bousquet","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jaci.2020.07.007","article-title":"Rhinitis 2020: A practice parameter update","volume":"146","author":"Dykewicz","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaci.2019.06.049","article-title":"Next-generation Allergic Rhinitis and its Impact on Asthma guidelines for allergic rhinitis based on GRADE and real-world evidence","volume":"145","author":"Bousquet","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1111\/all.70305","article-title":"ARIA 2024\u20132025 Guideline Panel. Allergic Rhinitis and its Impact on Asthma (ARIA)-EAACI guidelines-2024-2025 revision: Part II\u2013guidelines on oral and ocular treatments","volume":"81","author":"Vieira","year":"2026","journal-title":"Allergy"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/WOX.0b013e318186fb3a","article-title":"H1 antihistamines: Current status and future directions","volume":"1","author":"Simons","year":"2008","journal-title":"World Allergy Organ. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.anai.2023.07.019","article-title":"Evidence-based use of antihistamines for treatment of allergic conditions","volume":"131","author":"Linton","year":"2023","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101272","DOI":"10.1016\/j.bjorl.2023.03.009","article-title":"Efficacy of different oral H1 antihistamine treatments on allergic rhinitis: A systematic review and network meta-analysis of randomized controlled trials","volume":"89","author":"Hong","year":"2023","journal-title":"Braz. J. Otorhinolaryngol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.jaip.2025.12.034","article-title":"Efficacy and safety of oral antihistamines for allergic rhinitis: Network meta-analysis","volume":"14","author":"Vieira","year":"2026","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: Many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"ref_12","unstructured":"Maya Viejo, J.D., Navarro i Ros, F.M., Trillo-Calvo, E., and Rodr\u00edguez, L.R. (2026). Retrospectively Registered Protocol, Statistical Analysis Plan, and Methodological Audit Trail for Oral Second-Generation H1-Antihistamine Regimens for Allergic Rhinitis: Systematic Review and Network Meta-Analysis of Effects and Estimability. OSF Regist."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: An extension to the PRISMA statement for reporting literature searches in systematic reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2019). Undertaking network meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons. [2nd ed.].","DOI":"10.1002\/9781119536604"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1046\/j.1398-9995.2003.00261.x","article-title":"Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period","volume":"58","author":"Philip","year":"2003","journal-title":"Allergy"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13223-017-0183-z","article-title":"Efficacy and safety of setipiprant in seasonal allergic rhinitis: Results from phase 2 and phase 3 randomized, double-blind, placebo- and active-referenced studies","volume":"13","author":"Ratner","year":"2017","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.alit.2018.08.011","article-title":"Efficacy and safety of rupatadine in Japanese patients with seasonal allergic rhinitis: A double-blind, randomized, multicenter, placebo-controlled clinical trial","volume":"68","author":"Okubo","year":"2019","journal-title":"Allergol. Int."},{"key":"ref_21","unstructured":"U.S. Food and Drug Administration (2018). Allergic Rhinitis: Developing Drug Products for Treatment\u2014Guidance for Industry."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2222.1991.tb00807.x","article-title":"Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis","volume":"21","author":"Juniper","year":"1991","journal-title":"Clin. Exp. Allergy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0091-6749(99)70380-5","article-title":"Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire","volume":"104","author":"Juniper","year":"1999","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e073725","DOI":"10.1136\/bmj-2022-073725","article-title":"CONSORT Harms 2022 statement, explanation, and elaboration: Updated guideline for the reporting of harms in randomised trials","volume":"381","author":"Junqueira","year":"2023","journal-title":"BMJ"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2019). Adverse effects. Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons. [2nd ed.].","DOI":"10.1002\/9781119536604"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/j.1365-2222.2009.03257.x","article-title":"Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: A randomized, double-blind, parallel-group study","volume":"39","author":"Kuna","year":"2009","journal-title":"Clin. Exp. Allergy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0091-6749(96)70135-5","article-title":"Interpretation of Rhinoconjunctivitis Quality of Life Questionnaire data","volume":"98","author":"Juniper","year":"1996","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jaip.2016.02.006","article-title":"Minimal clinically important difference in allergic rhinitis: Agency for Healthcare Research and Quality or anchor-based thresholds?","volume":"4","author":"Meltzer","year":"2016","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: A generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med. Decis. Mak."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v106.i02","article-title":"netmeta: An R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"J. Stat. Softw."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: Inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med. Decis. Mak."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Nikolakopoulou, A., Higgins, J.P.T., Papakonstantinou, T., Chaimani, A., Del Giovane, C., Egger, M., and Salanti, G. (2020). CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLoS Med., 17.","DOI":"10.1371\/journal.pmed.1003082"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Bonner","year":"2018","journal-title":"J. Clin. Epidemiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jclinepi.2018.11.025","article-title":"GRADE approach to rate the certainty from a network meta-analysis: Addressing incoherence","volume":"108","author":"Mustafa","year":"2019","journal-title":"J. Clin. Epidemiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jclinepi.2018.08.022","article-title":"GRADE approach to rate the certainty from a network meta-analysis: Avoiding spurious judgments of imprecision in sparse networks","volume":"105","author":"Murad","year":"2019","journal-title":"J. Clin. Epidemiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jclinepi.2021.07.011","article-title":"GRADE guidelines 33: Addressing imprecision in a network meta-analysis","volume":"139","author":"Guyatt","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Chiocchia, V., Nikolakopoulou, A., Higgins, J.P.T., Page, M.J., Papakonstantinou, T., Cipriani, A., Furukawa, T.A., Siontis, G.C.M., Egger, M., and Salanti, G. (2021). ROB-MEN: A tool to assess risk of bias due to missing evidence in network meta-analysis. BMC Med., 19.","DOI":"10.1186\/s12916-021-02166-3"},{"key":"ref_42","unstructured":"R Core Team (2026). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing."},{"key":"ref_43","unstructured":"Stan Development Team (2026, July 29). CmdStan User\u2019s Guide, Version 2.39; Stan Development Team. Available online: https:\/\/mc-stan.org\/docs\/2_39\/cmdstan-guide-2_39.pdf."},{"key":"ref_44","unstructured":"Gabry, J., \u010ce\u0161novar, R., Johnson, A., and Bronder, S. (2026, July 29). CmdStanR: R Interface to CmdStan, R Package Version 0.9.0. Available online: https:\/\/mc-stan.org\/cmdstanr\/."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1214\/20-BA1221","article-title":"Rank-normalization, folding, and localization: An improved R-hat for assessing convergence of MCMC","volume":"16","author":"Vehtari","year":"2021","journal-title":"Bayesian Anal."},{"key":"ref_46","unstructured":"Talts, S., Betancourt, M., Simpson, D., Vehtari, A., and Gelman, A. (2018). Validating Bayesian inference algorithms with simulation-based calibration. arXiv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0149-2918(97)80115-4","article-title":"The effect of fluticasone propionate aqueous nasal spray on eosinophils and cytokines in nasal secretions of patients with ragweed allergic rhinitis","volume":"19","author":"Blomgren","year":"1997","journal-title":"Clin. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2500\/aap.2009.30.3204","article-title":"Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy","volume":"30","author":"Andrews","year":"2009","journal-title":"Allergy Asthma Proc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1398-9995.1998.tb03798.x","article-title":"Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis","volume":"53","author":"Bachert","year":"1998","journal-title":"Allergy"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jaci.2004.05.070","article-title":"Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis","volume":"114","author":"Bachert","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1398-9995.2008.01813.x","article-title":"Comparison of the efficacy and safety of bilastine 20 mg versus desloratadine 5 mg in seasonal allergic rhinitis patients","volume":"64","author":"Bachert","year":"2009","journal-title":"Allergy"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1081-1206(10)62086-8","article-title":"Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion","volume":"89","author":"Berger","year":"2002","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1034\/j.1398-9995.1999.00984.x","article-title":"A 12-week, placebo-controlled study of the efficacy and safety of ebastine 10 and 20 mg once daily in the treatment of perennial allergic rhinitis","volume":"54","author":"Bousquet","year":"1999","journal-title":"Allergy"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000316351","article-title":"Efficacy of desloratadine in persistent allergic rhinitis: A GA2LEN study","volume":"153","author":"Bousquet","year":"2010","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0091-6749(95)70001-3","article-title":"Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis","volume":"96","author":"Bronsky","year":"1995","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0091-6749(96)80065-0","article-title":"Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis","volume":"97","author":"Bronsky","year":"1996","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2500\/108854198778604112","article-title":"Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies","volume":"19","author":"Bronsky","year":"1998","journal-title":"Allergy Asthma Proc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2500\/108854199778553046","article-title":"Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis","volume":"20","author":"Casale","year":"1999","journal-title":"Allergy Asthma Proc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1081-1206(10)61576-1","article-title":"Montelukast for treating fall allergic rhinitis: Effect of pollen exposure in three studies","volume":"92","author":"Chervinsky","year":"2004","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2165\/00044011-199816060-00001","article-title":"Efficacy and tolerability comparison of ebastine 10 and 20 mg with loratadine 10 mg: A double-blind, randomised study in patients with perennial allergic rhinitis","volume":"16","author":"Davies","year":"1998","journal-title":"Clin. Drug Investig."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S1081-1206(10)60191-3","article-title":"Desloratadine for the treatment of cypress pollen-induced allergic rhinitis","volume":"103","author":"Demoly","year":"2009","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/j.1398-9995.2008.01668.x","article-title":"A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily in the treatment of persistent allergic rhinitis","volume":"63","author":"Fantin","year":"2008","journal-title":"Allergy"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2500\/aap.2015.36.3860","article-title":"A comparison of fluticasone propionate nasal spray and cetirizine in ragweed fall seasonal allergic rhinitis","volume":"36","author":"Ford","year":"2015","journal-title":"Allergy Asthma Proc."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1081-1206(10)61959-X","article-title":"Mizolastine provides effective symptom relief in patients suffering from perennial allergic rhinitis: A double-blind, placebo-controlled study versus loratadine","volume":"89","author":"Leynadier","year":"2002","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000331329","article-title":"The loss of smell in persistent allergic rhinitis is improved by levocetirizine due to reduction of nasal inflammation but not nasal congestion: The CIRANO study","volume":"158","author":"Guilemany","year":"2012","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/030006058501300507","article-title":"Comparative study of the efficacy, tolerance and side-effects of dexchlorpheniramine maleate 6 mg twice daily with terfenadine 60 mg twice daily","volume":"13","author":"Gutkowski","year":"1985","journal-title":"J. Int. Med. Res."},{"key":"ref_67","first-page":"56","article-title":"A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine 20 mg and 10 mg to loratadine 10 mg once daily in seasonal allergic rhinitis","volume":"14","author":"Hampel","year":"2004","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_68","first-page":"762","article-title":"Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis","volume":"98","author":"Harvey","year":"1996","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/j.1398-9995.2009.02096.x","article-title":"Desloratadine relieves nasal congestion and improves quality of life in persistent allergic rhinitis","volume":"64","author":"Holmberg","year":"2009","journal-title":"Allergy"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1081-1206(10)60914-3","article-title":"Desloratadine therapy for symptoms associated with perennial allergic rhinitis","volume":"96","author":"Kim","year":"2006","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2217\/thy.09.1","article-title":"Rupatadine 10 and 20 mg are effective and safe in the treatment of perennial allergic rhinitis after 4 weeks of treatment: A randomized, double-blind, controlled trial with loratadine and placebo","volume":"6","author":"Kowalski","year":"2009","journal-title":"Therapy"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3109\/02770900903104540","article-title":"Clinical studies of combination montelukast and loratadine in patients with seasonal allergic rhinitis","volume":"46","author":"Lu","year":"2009","journal-title":"J. Asthma"},{"key":"ref_73","first-page":"31","article-title":"A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: A randomized, double-blind, placebo-controlled study","volume":"6","author":"Lukat","year":"2013","journal-title":"J. Asthma Allergy"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/archoto.2010.128","article-title":"Rupatadine and levocetirizine for seasonal allergic rhinitis: A comparative study of efficacy and safety","volume":"136","author":"Maiti","year":"2010","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4103\/0976-500X.85958","article-title":"Olopatadine hydrochloride and rupatadine fumarate in seasonal allergic rhinitis: A comparative study of efficacy and safety","volume":"2","author":"Maiti","year":"2011","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1185\/03007991003745233","article-title":"Study of levocetirizine in seasonal allergic rhinitis","volume":"26","author":"Mansfield","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_77","first-page":"27","article-title":"Morning and evening efficacy evaluation of rupatadine 10 and 20 mg compared with cetirizine 10 mg in perennial allergic rhinitis: A randomized, double-blind, placebo-controlled trial","volume":"4","author":"Marmouz","year":"2011","journal-title":"J. Asthma Allergy"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1067\/mai.2000.106040","article-title":"Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial","volume":"105","author":"Meltzer","year":"2000","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1081-1206(10)61249-5","article-title":"Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: Results of a single-center, placebo-controlled trial","volume":"96","author":"Meltzer","year":"2006","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"E702","DOI":"10.1002\/lary.28906","article-title":"Double-Blind Placebo-Controlled Trial of Controlled-Release Bepotastine Salicylate in Patients with Allergic Rhinitis","volume":"131","author":"Mo","year":"2021","journal-title":"Laryngoscope"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2217\/thy.10.40","article-title":"Rupatadine 10 mg in adolescent and adult symptom relief of perennial allergic rhinitis","volume":"7","author":"Molina","year":"2010","journal-title":"Therapy"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S1081-1206(10)62991-2","article-title":"Comparison of efficacy and safety of cetirizine and ebastine in patients with perennial allergic rhinitis","volume":"80","author":"Melac","year":"1998","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1081-1206(10)61891-1","article-title":"Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled trial performed in the fall","volume":"88","author":"Nayak","year":"2002","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2222.2003.01596.x","article-title":"Health-related quality-of-life effects of once-daily cetirizine HCl in patients with seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial","volume":"33","author":"Noonan","year":"2003","journal-title":"Clin. Exp. Allergy"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000083322","article-title":"Fexofenadine improves quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season","volume":"136","author":"Okubo","year":"2005","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_86","unstructured":"Organon and Co (2026, July 18). A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Study the Efficacy and Safety of MK-4117 (Desloratadine) in Japanese Subjects with Seasonal Allergic Rhinitis. ClinicalTrials.gov Identifier: NCT02320396, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02320396."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2222.2002.01422.x","article-title":"Montelukast for treating seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial performed in the spring","volume":"32","author":"Philip","year":"2002","journal-title":"Clin. Exp. Allergy"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2500\/aap.2007.28.3000","article-title":"Efficacy of montelukast for treating perennial allergic rhinitis","volume":"28","author":"Philip","year":"2007","journal-title":"Allergy Asthma Proc."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1034\/j.1398-9995.2003.00171.x","article-title":"Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult perennial allergic rhinitis sensitized to house dust mites","volume":"58","author":"Potter","year":"2003","journal-title":"Allergy"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1398-9995.2007.01374.x","article-title":"Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis","volume":"62","author":"Pradalier","year":"2007","journal-title":"Allergy"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2500\/aap.2009.30.3228","article-title":"Efficacy and safety of fixed-dose loratadine\/montelukast in seasonal allergic rhinitis: Effects on nasal congestion","volume":"30","author":"Prenner","year":"2009","journal-title":"Allergy Asthma Proc."},{"key":"ref_92","first-page":"118","article-title":"A comparison of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis","volume":"47","author":"Ratner","year":"1998","journal-title":"J. Fam. Pract."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1159\/000077357","article-title":"Efficacy and safety of ebastine 20 mg compared with loratadine 10 mg once daily in seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled study","volume":"133","author":"Ratner","year":"2004","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Salmun, L.M., and Lorber, R. (2002). 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. BMC Fam. Pract., 3.","DOI":"10.1186\/1471-2296-3-14"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1185\/03007995.2011.640667","article-title":"Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis","volume":"28","author":"Sastre","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.anai.2009.12.003","article-title":"Efficacy and safety of levocetirizine in improving symptoms and health-related quality of life in US adults with seasonal allergic rhinitis: A randomized, placebo-controlled study","volume":"104","author":"Segall","year":"2010","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1067\/mai.2003.168","article-title":"Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis","volume":"111","author":"Simons","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0091-6749(88)91045-7","article-title":"Double-blind placebo-controlled study of loratadine, mequitazine, and placebo in the symptomatic treatment of seasonal allergic rhinitis","volume":"81","author":"Bousquet","year":"1988","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2500\/aap.2014.35.3760","article-title":"Effect of cetirizine on symptom severity and quality of life in perennial allergic rhinitis","volume":"35","author":"Skoner","year":"2014","journal-title":"Allergy Asthma Proc."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S1081-1206(10)62144-8","article-title":"Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis","volume":"90","author":"Philip","year":"2003","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1001\/archinte.1994.00420230086010","article-title":"Intranasal fluticasone propionate is more effective than terfenadine tablets for seasonal allergic rhinitis","volume":"154","author":"Findlay","year":"1994","journal-title":"Arch. Intern. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1046\/j.1365-2222.2000.00914.x","article-title":"Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis","volume":"30","author":"Juniper","year":"2000","journal-title":"Clin. Exp. Allergy"},{"key":"ref_103","first-page":"346","article-title":"Efficacy and safety of rupatadine fumarate in the treatment of perennial allergic rhinitis: A multicenter, double-blinded, randomized, placebo-controlled bridging study in Koreans","volume":"42","author":"Won","year":"2024","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1016\/j.jaip.2024.09.001","article-title":"Allergic Rhinitis and its Impact on Asthma 2024 Guideline Panel. Intranasal versus oral treatments for allergic rhinitis: A systematic review with meta-analysis","volume":"12","author":"Torres","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_105","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (2026, July 28). StopCold 5 mg\/120 mg comprimidos de liberaci\u00f3n prolongada: Ficha T\u00e9cnica. Centro de Informaci\u00f3n Online de Medicamentos de la AEMPS (CIMA). Available online: https:\/\/cima.aemps.es\/cima\/pdfs\/ft\/62102\/FT_62102.pdf."},{"key":"ref_106","first-page":"91","article-title":"Cetirizine and pseudoephedrine retard alone and in combination in the treatment of perennial allergic rhinitis: A double-blind multicentre study","volume":"34","author":"Bertrand","year":"1996","journal-title":"Rhinology"},{"key":"ref_107","first-page":"67","article-title":"Cetirizine and pseudoephedrine retard, given alone or in combination, in patients with seasonal allergic rhinitis","volume":"35","author":"Grosclaude","year":"1997","journal-title":"Rhinology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"160018","DOI":"10.1038\/sdata.2016.18","article-title":"The FAIR guiding principles for scientific data management and stewardship","volume":"3","author":"Wilkinson","year":"2016","journal-title":"Sci. Data"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7169\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:12:43Z","timestamp":1789474363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":108,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15187169"],"URL":"https:\/\/doi.org\/10.3390\/jcm15187169","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}